603 related articles for article (PubMed ID: 16619467)
1. From Asilomar to industrial biotechnology: risks, reductionism and regulation.
Krimsky S
Sci Cult (Lond); 2005 Dec; 14(4):309-23. PubMed ID: 16619467
[No Abstract] [Full Text] [Related]
2. Asilomar's legacy in Aotearoa New Zealand.
Rogers-Hayden T
Sci Cult (Lond); 2005 Dec; 14(4):393-410. PubMed ID: 16622954
[No Abstract] [Full Text] [Related]
3. Recombinant DNA and the regulation of biotechnology: reflections on the Asilomar Conference, ten years after.
Barkstrom JE
Akron Law Rev; 1985; 19(1):81-126. PubMed ID: 11650740
[No Abstract] [Full Text] [Related]
4. The challenge of biotechnology.
Gore A; Owens S
Yale Law Policy Rev; 1985; 3(2):336-57. PubMed ID: 11652468
[No Abstract] [Full Text] [Related]
5. Regulating biotechnology.
McGarity TO
Issues Sci Technol; 1985; 1(3):40-56. PubMed ID: 11649701
[No Abstract] [Full Text] [Related]
6. The long and winding road from Asilomar to Brussels: science, politics and the public in biotechnology and regulation.
Abels G
Sci Cult (Lond); 2005 Dec; 14(4):339-53. PubMed ID: 16619469
[No Abstract] [Full Text] [Related]
7. Molecular politics in a global economy.
Wright S
Politics Life Sci; 1996 Sep; 15(2):249-63. PubMed ID: 11654797
[No Abstract] [Full Text] [Related]
8. Corporate responsibility for recombinant DNA activities.
Berger BA
Univ Toledo Law Rev; 1981; 12(4):913-24. PubMed ID: 11649592
[No Abstract] [Full Text] [Related]
9. Transnationalizing recombinant-DNA regulation: between Asilomar, EMBO, the OECD, and the European Community.
Gottweis H
Sci Cult (Lond); 2005 Dec; 14(4):325-38. PubMed ID: 16619468
[No Abstract] [Full Text] [Related]
10. Recombinant DNA research: proposed actions under the guidelines; notice.
U.S. National Institutes of Health
Fed Regist; 1997 Feb; 62(31):7108-23. PubMed ID: 11654870
[No Abstract] [Full Text] [Related]
11. Recombinant regulation: the Asilomar legacy 30 years on.
Hindmarsh R; Gottweis H
Sci Cult (Lond); 2005 Dec; 14(4):299-307. PubMed ID: 16619466
[No Abstract] [Full Text] [Related]
12. Coordinated framework for regulation of biotechnology; establishment of the Biotechnology Science Coordinating Committee; notice.
U.S. Office of Science and Technology Policy
Fed Regist; 1985 Nov; 50(220):47174-95. PubMed ID: 11655733
[No Abstract] [Full Text] [Related]
13. NIH guidelines for research involving recombinant DNA molecules.
Wilson DJ
Account Res; 1993; 3(2-3):177-85. PubMed ID: 11652293
[No Abstract] [Full Text] [Related]
14. Human gene therapy: application, ethics and regulation.
Baskerville G
Dickinson Law Rev; 1992; 96(4):733-63. PubMed ID: 11652212
[No Abstract] [Full Text] [Related]
15. Regulation of genetic engineering: less concern about Frankensteins but time for action on commercial production.
Karny GM
Univ Toledo Law Rev; 1981; 12(4):815-68. PubMed ID: 11649588
[No Abstract] [Full Text] [Related]
16. Coordinated framework for regulation of biotechnology; announcement of policy; notice for public comment.
U.S. Office of Science and Technology Policy
Fed Regist; 1986 Jun; 51(123):23302-50. PubMed ID: 11655807
[No Abstract] [Full Text] [Related]
17. Genetic engineering regulation in Australia: an 'archaeology' of expertise and power.
Hindmarsh R
Sci Cult (Lond); 2005 Dec; 14(4):373-92. PubMed ID: 16622953
[No Abstract] [Full Text] [Related]
18. The biotechnology revolution and its regulatory evolution.
Hoffman DE
Drake Law Rev; 1988-1989; 38(3):471-550. PubMed ID: 16086466
[No Abstract] [Full Text] [Related]
19. Plan to end genetics panel troubles EPA.
Science; 1996 Aug; 273(5278):1035. PubMed ID: 11644823
[No Abstract] [Full Text] [Related]
20. The regulation of recombinant DNA research: the alternative of local control.
Rosenblatt DP
Boston Coll Environ Aff Law Rev; 1982; 10(1):37-78. PubMed ID: 11649694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
